$0.33 $(0.09) $0.24
Basic - Class B common 0.28 (0.08) 0.20
Diluted - Class A common 0.31 (0.08) 0.23
Diluted - Class B common (f) 0.20
Shares used in per share
calculation:
Basic - Class A common 36,277 (435) (g) 35,842
Basic - Class B common 13,065 (147) (g) 12,918
Diluted - Class A common 50,729 (732) (g) 49,997
Diluted - Class B common (f) 13,113
Years ended March 31,
2005
As
Previously As
Reported Adjustments Restated
Net revenues $303,493 $1,163 (d) $304,656
Cost of sales 107,682 266 (d) 107,948
Gross profit 195,811 897 196,708
Operating expenses:
Research and development 23,538 - 23,538
Purchased in-process research and -
development and transaction
costs - - -
Selling and administrative 116,638 1,625 (a)(b) 118,263
Amortization of intangibles 4,653 - 4,653
Litigation (1,430) - (1,430)
Total operating expenses 143,399 1,625 145,024
Operating income 52,412 (728) 51,684
Other expense (income):
Interest
'/>"/>
SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Related medicine news :1.
His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States2.
Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 20083.
NUCRYST Pharmaceuticals announces year-end results4.
Renhuang Pharmaceuticals, Inc. Retains CCG Elite5.
MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process6.
Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities7.
Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications8.
American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals9.
Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation10.
MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product11.
Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program